JAC Advance Access published online on January 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh055
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Sumitomo Pharmaceuticals
Research Division, 1-98, Kasugadenaka 3-chome, Konohana-ku,
Osaka 554-0022;
* Corresponding author. E-mail: ktakemot{at}sumitomopharm.co.jp.
Received 17 July 2003
; revised 19 October 2003
; accepted 5 November 2003
Objectives: The efficacy of intravenous
injections of a liposomal formulation of amphotericin B (AmBisome) and
amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent
and temporarily leucopenic mouse models of disseminated aspergillosis
using seven isolates of Aspergillus. Methods: Mice were infected with the organisms
via tail veins. At 4 h after infection, antifungals were administered
intravenously. For 30 days the number of mice surviving was recorded. Results: AmBisome at 1 mg/kg or higher significantly
prolonged the survival time of mice infected with five out
of seven isolates of Aspergillus compared with
the control group. There was no difference in
in vivo activity between AmBisome and Fungizone
at 1 mg/kg in six isolates of Aspergillus. At the
maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg)
showed greater efficacy than Fungizone (1 mg/kg). Conclusions: These results suggest that the
overall protective activity of AmBisome against disseminated aspergillosis
is superior to that of Fungizone.
Keywords: liposomal amphotericin B, amphotericin B deoxycholate, Aspergillus, tolerability
Comparative studies on the efficacy of AmBisome
and Fungizone in a mouse model of disseminated aspergillosis
2 Division
of Respiratory Disease, Department of Medicine, Kawasaki Medical
School, 577, Matsushima,
Kurashiki 701-0192, Japan
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Wang, L. Kong, J. Wang, X. He, X. Li, and Y. Xiao Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. PDA J. Pharm. Sci. Technol., March 1, 2009; 63(2): 159 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brock, G. Jouvion, S. Droin-Bergere, O. Dussurget, M.-A. Nicola, and O. Ibrahim-Granet Bioluminescent Aspergillus fumigatus, a New Tool for Drug Efficiency Testing and In Vivo Monitoring of Invasive Aspergillosis Appl. Envir. Microbiol., November 15, 2008; 74(22): 7023 - 7035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis J. Antimicrob. Chemother., April 1, 2006; 57(4): 724 - 731. [Abstract] [Full Text] [PDF]
|
|